Janssen’s Talvey secures FDA approval for multiple myeloma treatment
The FDA approval was based on results from the talquetamab Phase 2 MonumenTAL-1 study in which Talvey showed…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
11 Aug 23
The FDA approval was based on results from the talquetamab Phase 2 MonumenTAL-1 study in which Talvey showed…
11 Aug 23
Under the partnership, Lotus will oversee obtaining regulatory approval and will have the sole right to market Adlarity…
11 Aug 23
Preclinical research published in Nature Communications details safety and effectiveness of the investigational therapy now in a Phase…
10 Aug 23
Informally referred to as Eris, the new strain descends from the lineage of XBB.1.9.2, and would pose relatively…
10 Aug 23
At week 12, both Phase 3 studies' primary endpoints of absolute change from baseline in the weekly UAS7…
10 Aug 23
The acquisition expands Lilly's immunology portfolio to include DICE's novel oral therapeutic candidates, including oral IL-17 inhibitors currently…
10 Aug 23
VANFLYTA is not indicated as maintenance monotherapy following allogeneic hematopoietic stem cell transplantation (HSCT); improvement in overall survival…
09 Aug 23
Under the investment, SK bioscience will acquire a 7% stake or 6.5 million shares of Novavax’s common stock…
09 Aug 23
The company is planning to cut operations at its Canton, Massachusetts, facility and Rockville, Maryland factory and lay…
09 Aug 23
The cardiovascular outcomes trial evaluated subcutaneous once-weekly semaglutide 2.4mg against placebo as an adjunct to the standard of…